SZLS Share Price Performance
Recent SZLS News & Updates
No updates
StageZero Life Sciences Ltd. Key Details
Last Reported Earnings
Sep 30, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.10
- Gross Margin
- 6.39%
- Net Profit Margin
- -420.97%
- Debt/Equity Ratio
- -15.0%
StageZero Life Sciences Ltd. Competitors
About SZLS
- Founded
- n/a
- Employees
- 40
- CEO
- WebsiteView website
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
Canadian Market Performance
- 7 Days: -1.8%
- 3 Months: 7.8%
- 1 Year: 18.5%
- Year to Date: 8.6%
Over the last 7 days, the market has dropped 1.8%, driven by pullbacks in every sector, especially the Financials sector. In contrast to the last week, the market is actually up 19% over the past year. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading